EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis



RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis



Geburtshilfe und Frauenheilkunde 72(5): 385-391



In women, malignant breast tumours are among the most common malignant diseases in Europe. In advanced breast cancer, the risk of bone metastasis increases to 65-75 %. The discovery of the physiological bone metabolism parameters RANK (receptor activator of nuclear factor-κB), RANKL (receptor activator of nuclear factor-κB ligand) and OPG (osteoprotegerin) as well as their pathophysiological involvement in bone-related diseases is the subject of new therapeutic strategies. The formation of osteolytic bone metastasis requires increased osteoclast activity. Activation of osteoclasts by excessive direct RANKL or reduced OPG expression of osseous metastatic tumour cells remains to be elucidated. More than 50 % of primary breast cancer cells express OPG and RANK, while RANKL could be detected only in 14-60 %. Increased OPG concentrations in the serum of patients with bone metastases have been shown in several studies, whereas the RANKL results are described in an opposite manner. The use of OPG as a biomarker for the detection of osteolytic bone metastases is not consistent and needs to be proved in further studies. Increased RANKL activity was found in diseases characterised by excessive bone loss and formed the basis of new therapeutic options. In several studies, a human monoclonal antibody to RANKL (denosumab) was investigated for the treatment of bone diseases. Denosumab is a promising therapeutic option due to its bone-protective effects.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333138

Download citation: RISBibTeXText

PMID: 25298541

DOI: 10.1055/s-0031-1298276



Related references

Expression of RANK and RANKL is altered in invasive carcinoma and bone metastasis of breast cancer. Journal of Bone & Mineral Research 17(Suppl 1): S411, September, 2002

Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Research 33(1): 199-206, 2013

Involvement of RANKL/RANK pathway in bone metastasis in breast cancer. Clinical Calcium 21(8): 1159-1166, 2011

RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends in Endocrinology and Metabolism: Tem 22(5): 188-194, 2011

Opg, RANKl, and RANK in cancer metastasis: expression and regulation. Cancer Treatment and Research 118: 149-172, 2004

Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi 31(5): 684-689, 2013

Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. Plos One 8(3): E58361-E58361, 2013

The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis. Oncotarget 6(26): 22918-22933, 2016

Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells. Biochemical and Biophysical Research Communications 408(3): 411-416, 2011

RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Research 17(): 24-24, 2015

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biology & Therapy 9(7): 539-550, 2011

Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system. Medical Hypotheses 81(5): 805-806, 2014

RANK expression on breast cancer cells promotes skeletal metastasis. Clinical & Experimental Metastasis 31(2): 233-245, 2014

Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. Journal of Korean Medical Science 18(4): 541-546, 2003

Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. Oncology Reports 32(6): 2605-2611, 2015